• A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

  NCT04161898

  Active, not recruitingInterventionalPhase 3Updated Feb 18, 2026
• A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

  NCT06498089

  RecruitingInterventionalPhase 4Updated Oct 17, 2024
• Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

  NCT05151848

  Unknown statusInterventionalPhase 4Updated Jul 24, 2023
• A Pilot Study in Severe Patients With Takayasu Arteritis.

  NCT04300686

  RecruitingInterventionalPhase 4Updated Aug 10, 2021
• Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

  NCT05749666

  Unknown statusInterventionalPhase 3Updated Mar 1, 2023
• Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients

  NCT07477795

  Not yet recruitingInterventionalPhase 2Updated Mar 27, 2026

ClinicalTrials.gov ID

NCT07451665

Lead Sponsor

Chinese SLE Treatment And Research GroupOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

180Estimated

Last Update Posted

Mar 5, 2026Actual

Start Date

Apr 1, 2026Estimated

Primary Completion Date

Mar 31, 2029Estimated

Completion Date

Mar 31, 2029Estimated

Official Title

A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial

Brief Summary

This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.

Detailed Description

In this study, 180 Takayasu's arteritis patients with active disease will be enrolled. Patients are randomized in to the vunakizumab treatment group, ivarmacitinib treatment group and glucocorticoid treatment group. Patients will follow the same reduction steps for glucocorticoids. The primary endpoint is the percentage of patients who are in complete response at week 52.

The efficacy will be evaluated at week 4, 12, 26, 38 and 52. Safety is also monitored during the study.

• Takayasu Arteritis (TAK)

• Vanakizumab
• Ivarmacitinib
• Prednisone

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• a. Adult patients (aged between 18-70 years) fulfilling the 2022 ACR/EULAR classification criteria for TAK with new-onset or relapsing disease.
• b. Presence of active disease despite treatment with gluccorticoids combined with a conventional synthetic or biologic immunosuppressive agent other than JAK inhibitors and IL-17 inhibitors, including new-onset patients and relapsed patients.

Patient is considered to have active disease by the investigator is the patients meets at least two of the following three criteria: i) one or more clinical manifestations determined by the investigator to be due to active TAK; ii) one or more findings on imaging of progressive disease; or iii) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Clinical criteria included constitutional symptoms (fever, fatigue, and weight loss), musculoskeletal symptoms, vascular pain, neurological or visual symptoms, abdominal pain or angina, new or worsening limb claudication, loss of pulses, and worsening hypertension. Imaging criteria includes new vascular stenosis or aneurysms detected by ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography.

Exclusion Criteria:

• Participants are excluded from the study if any of the following criteria apply:

  1. Medical Conditions

     1. Severe disease from TAK for which urgent treatment with interventional vascular procedures or bypass surgery is considered necessary
     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia, that is anticipated to need treatment during the study
     3. Active hepatitis B or C virus infection
     4. Active tuberculosis (Patients with latent tuberculosis infection could be enrolled with preventive therapy for tuberculosis flare)
     5. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)
     6. Poorly controlled diabetes
     7. Patients with history of venous thrombosis
     8. Upper GI bleeding within 3 months prior to enrollment
     9. Uncontrolled heart failure
     10. Refractory hypertension

  2. Abnormal Laboratory Test Findings k. Serum liver enzyme elevation 3 times higher than the upper limits of normal range l. Severe renal function impairment with estimated glomerular filtration rate ≤ 30 ml/minute/1.73 m2, calculated using the Modification of Diet in Renal Disease equation (doi:10.1056/NEJMoa2102953)

  3. Other Exclusion Criteria m. Females who are pregnant or intend to be pregnant during the time frame of the study n. History of treatment with JAKi or IL-17i. o. Any other medical, psychiatric, and/or social reason as determined by the investigator to be a contraindication for study participation

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Chinese SLE Treatment And Research GroupOTHER

liu_dz2001@sina.com+86-13802257360

yaodongyun88@163.com+86-13939199823

yongchy@sina.com+86-13813892892